Liquid Biopsy Market
The future of the global liquid biopsy market looks promising with opportunities in the reference laboratory, hospital & physician laboratory, and academic & research center markets. The global liquid biopsy market is expected to reach an estimated $12.4 million by 2035 from $7.1 million in 2027 with a CAGR of 7.2% from 2027 to 2035. The major drivers for this market are the increasing use of precision medicine is driving market expansion, the rising need for non-invasive diagnosis solution, and the growing use of liquid biopsy in treatment monitoring.
- Lucintel forecasts that, within the product category, assay kits is expected to witness the highest growth over the forecast period due to the increasing demand for accurate and rapid testing.
- Within the end use category, hospitals & physician laboratories is expected to witness the highest growth over the forecast period due to the growing adoption of liquid biopsy diagnostics in hospitals.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the rising cancer prevalence and expanding diagnostic infrastructure.
Emerging Trends in Liquid Biopsy Market
Considering how the liquid biopsy market will develop in the coming years, it is likely that specialized tests will be replaced by routine cancer management tests. Clinical validation, reimbursement, and standardization of labs will become as important as the sensitivity of the assays. Lucintel predicts the use of liquid biopsy will expand to cancer screening, selection of cancer treatment, and determination of cancer recurrence. However, the evidence requirement will be very stringent.
- Early Cancer Detection: Multi-cancer early detection programs are underway large, prospective studies. Other blood-based programs, like Guardant's Shield, are also gaining interest. For now, the standard for colorectal cancer (CRC) is to screen adults aged 45-75. The field may change in the next 3-5 years if blood-based programs show a reduction in CRC mortality.
- Therapy Selection: NGS-based circulating tumor DNA is becoming a practical alternative to tissue-based testing, particularly for situations where a tissue biopsy is unsafe or insufficient. Compassionate use/FDA expanded access pathways continue to shape the adoption of molecular testing.
- Minimal Residual Disease: Multiple studies demonstrate that ctDNA testing can provide early detection of tumor recurrence months prior to conventional imaging in breast, lung, and colon cancers. Within the next 3-5 years, the use of liquid biopsies to determine MRD may assist in therapeutic decision-making.
- Automation and Standardization: A focus on automation and standardization of laboratory processes will help address the challenges of reproducibility and turn-around time, and aid the testing and processing of large numbers of specimens. Standardization will help laboratories meet the requirements for accreditation.
- Reimbursement and Decentralization: The adoption of home-based health and decentralized health systems creates opportunities for diagnostic labs to change their focus to support and service offerings, particularly in the collection and processing of specimens.
Most industries are shaped by broad-reaching trends, but few as clearly as the diagnostic industry. The commercial focus on oncology will expand to include other cancer types as well as therapeutic monitoring and MRD. Vendors that combine regulatory and performance boundaries will find success.
Recent Developments in the Liquid Biopsy Market
Lucintel Has Identified Three Key Areas for Long-term Growth in The liquid biopsy market: Increased regulatory scope, increased market competition, and expanded reimbursement.
- Regulatory Scope: Guardant Health's July 2024 FDA approval for Shield, its blood-based colorectal cancer (CRC) screening test, sets a key commercial milestone for 2025. Broader regulatory approvals will build the confidence level of the physician community and encourage the initiation of discussions with payers for coverage and reimbursement of population-based cancer screening.
- Pharma Partnerships: The expansion of biomarker-led oncology collaborations around antibody-drug conjugates by AstraZeneca and Daiichi Sankyo in 2025, increased the requirement for circulating tumor DNA (ctDNA) and resistance monitoring. Liquid biopsies are likely to become routine in the selection of treatment and patient enrollment in clinical trials.
- Production Expansion: In 2025, Natera scaled the Signatera assay to meet additional demand for adjuvant cancer monitoring and clinical research. Increased laboratory capacity should reduce turnaround times, enable higher testing volumes, and strengthen the economic feasibility of testing.
- Technology Launches: There were advances in the areas of multi-cancer early detection and methylation-based early detection in 2025. Further development in these areas will depend on evidence and the ability to control false positives.
- Strategic Collaborations: In 2025, Illumina partnered with a cloud and an artificial intelligence (AI) company, to provide liquid biopsy developers with greater access to high-throughput sequencing and lower the barrier to bioinformatics. These advances should enable smaller companies to enter the market. However, governance of patient data will limit commercialization.
Commercial positions will be strengthened by partnerships and evidence-based indications in the next five years as opposed to broad technology claims. Liquid biopsy has the potential to shift from specialist to routine oncology testing, subject to clinical validation and reimbursement. The most commercially successful positions will be held by the most sensitive and rapid platforms that provide actionable results.
Strategic Growth Opportunities in the Liquid Biopsy Market
Commercial demand is migrating toward earlier and more data-rich cancer management. Between 2024 and 2026, falling costs of and progress in sequencing, as well as changes in reimbursement and clinical validation, will drive an expansion of the addressable market for oncology testing. From Lucintel's perspective, liquid biopsy has the potential to complement imaging and tissue biopsy in cancer diagnosis and management.
- Early Cancer Detection: A number of large, high-profile, and well-funded trials are underway to test multi-cancer early detection (MCED) and multi-cancer screening (MCS) technologies, which, if proven to have broad sensitivity and an acceptable rate of false positives, could create a significant market for preventive testing. The NHS-Galleri randomized controlled trial to evaluate the use of Galleri as a screening tool for the early detection of cancer reported in May 2025 that it had enrolled over 140,000 participants. In the next three to five years, if validated liquid biopsy technologies became available, liquid biopsy market demand could potentially migrate into primary care and employer-sponsored screening.
- Therapy Selection: Particularly when sufficient tissue is unavailable or too dangerous to obtain, genomic profiling from blood can facilitate the selection of personalized therapy. In January 2025, Guardant Health reported its tests were used by over 10,000 oncologists. Rapid biomarker turnaround times for all solid tumors will become a standard of care and further drive the need for their tests.
- Minimal Residual Disease Monitoring: Once treatment is initiated, ctDNA testing can be used to determine if the tumor has returned, potentially even before it is visible on traditional imaging. In March 2025, Natera announced Signatera had processed over 100,000 tests since launch. If ctDNA testing is conducted on a recurring basis, it could make potential changes in a patient's therapy before relapse.
- Pharmaceutical Trials: Centralized liquid biopsy services for pharmacodynamics and efficacy endpoints will be in high demand for various clinical trials. In February 2025, the FDA reported over 100 oncology therapeutics with companion diagnostics. With improved patient stratification and the use of decentralized sampling, clinical trials could be reduced from three to five years to as little as one to two years.
- Geographic Expansion: Testing providers can expand into regions with limited pathology capacity through local lab partnerships. India's cancer burden is estimated to be about 1.6 million new cases each year (ICMR-linked, Apr 2025). Lower volume blood collection and digital interpretation can improve access in growing health care systems.
Long term economics will be driven by recurring testing rather than one time diagnosis. The greatest opportunity will be for companies who determine clinical utility and get reimbursement, and integrate the testing results in the oncology workflow. Price discipline is still relevant. Evidence must show testing provides fewer invasive procedures or gives better options for treatment. Partnering with labs, hospitals and pharma will likely be more effective than going it alone with tests.
Liquid Biopsy Market Drivers and Challenges
The markets for liquid biopsy tests are expected to be heavily influenced by the next generations of technology, the increasing incidence of cancer, the changing economics of the healthcare system and the healthcare payor system, as well as the changing regulatory policies. There is an increasing demand for minimally invasive methods for diagnosis and for the selection of treatment and monitoring for various cancers. Further, technological advancements in the areas of sequencing and artificial intelligence have expanded the scope of clinical applications of liquid biopsy tests. The development and implementation of clinical guidelines and reimbursement policies are expected to be key areas of focus in the near future. Lucintel expects the market will continue to evolve in the direction of these key, interacting factors.
The factors responsible for driving this market include :
- Increasing Cancer Burden: A greater number of cancer cases leads to the demand for faster diagnosis, cancer treatment monitoring and detection of cancer recurrence. Liquid biopsy offers the ability to perform repeated blood tests, which is less invasive compared to tissue biopsy. The World Health Organization projected, in January 2025, over 35 million new cancer cases are expected annually by 2050, which indicates the rising need for oncology diagnostics. In the coming years, oncology workloads will continue to increase, and the need for scalable diagnostic tests will increase as well.
- Advancements in Technology: PCR and AI are increasing the sensitivity and specificity of detecting circulating tumor DNA. In March 2025, studies focused on multi-cancer early detection continued and some involved thousands of participants. Over the next three to five years, the ability to detect and monitor therapy response, along with assessment of residual disease using liquid biopsy, will increase.
- Demand for Personalized Treatment: The use of liquid biopsy provides the ability to perform repeated molecular testing which is essential for cancer treatment. In February 2025, precision-oncology programs continued to expand the genomic testing offered to patients with advanced cancers, where treatment may depend on multiple biomarkers. Over the next three to five years, the use of targeted and combination therapies will increase, thus increasing the need for rapid, repeated molecular testing.
The challenges facing this market include:
- Regulatory and Clinical Acceptance: Regulatory progress and the accumulation of clinical data are improving the acceptance of liquid biopsy products. In July 2024, the first blood-based colorectal cancer screening test received authorization from the FDA. In 2025, other validation studies and professional society discussions and meetings also impacted market access. In the next 3-5 years, better definition of clinical pathways, standardization of performance requirements, and more extensive evidence will influence reimbursement and integration in the regular practice of oncology.
- Manufacturing and Cost: A variety of technology improvements are driving down the costs of liquid biopsy. These improvements, along with scale, will facilitate access and expansion of liquid biopsy in central and regional labs. These will support the use of liquid biopsy for monitoring, selecting therapy, and in large-scale population diagnostic tests. In 2025, automation in biopsy collection and process improvement were described. In 2025, research on liquid biopsy was extensive, and the need for large-scale, prospective studies for validation was stressed. In the next 3-5 years, insufficient validation and case studies to support the use of liquid biopsy may result in caution by payers and professional societies, restricted reimbursement, and reliance on established diagnostic tests.
- Reimbursement and Cost Barriers: Expenses associated with testing, the establishment of a robust laboratory infrastructure, and payer variation have impacted the adoption of molecular diagnostics. As of June 2025, healthcare providers were continuing to evaluate the economic value of advanced molecular tests against competing diagnostic pathways. In the next three to five years, the lack of assurance by payers for advanced molecular diagnostics may compel healthcare providers to assess the economic value of molecular diagnostics in comparison to alternative diagnostic tests, and healthcare technology manufacturers may need to generate health-economic evidence that advanced molecular tests lead to reduced hospital stays, faster selection of an oncologic treatment, and/or improved health outcomes of the patient.
The market for liquid biopsy is expected to grow due to rising incidence of cancers, the need for personalized medicine, improving laboratory and technological advances. However, in the next three to five years, market leaders would be those companies that combined advanced molecular diagnostics with clear evidence of clinical utility and improved workflows, and stellar regulatory and reimbursement strategies. Initially, oncologic centers with the advanced molecular diagnostics infrastructure and a robust laboratory would adopt these advanced diagnostics.
List of Liquid Biopsy Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies liquid biopsy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy market companies profiled in this report include-
- Bio-Rad Laboratories
- QIAGEN
- MDxHealth
- Myriad Genetics
- Biocept, Inc.
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Cardiff Oncology
- Guardant Health
Liquid Biopsy Market by Segment
The study includes a forecast for the global liquid biopsy market by product, circulating biomarker, application, end use, and region.
Liquid Biopsy Market by Product [Value ($M) from 2019 to 2035]:
- Assays Kits
- Instruments
- Services
Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2019 to 2035]:
- Circulating Tumor Cells
- Circulating Tumor DNA
- Cell-Free DNA
- Extracellular Vesicles
- Others
Liquid Biopsy Market by Application [Value ($M) from 2019 to 2035]:
Liquid Biopsy Market by End Use [Value ($M) from 2019 to 2035]:
- Reference Laboratories
- Hospitals & Physician Laboratories
- Academic & Research Centers
- Others
Liquid Biopsy Market by Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Liquid Biopsy Market
The liquid biopsy market has experienced rapid growth driven by technological advancements, increasing adoption in clinical settings, and a rising prevalence of cancer worldwide. As healthcare systems evolve, countries are investing in innovative diagnostic tools to improve early detection, personalized treatment, and patient outcomes. Regulatory approvals and increased research funding further propel this sector forward. Each country's unique healthcare infrastructure, research capabilities, and market demands influence their development trajectory. Understanding these regional differences is crucial for stakeholders aiming to capitalize on emerging opportunities in the liquid biopsy landscape.
- United States: The US leads the liquid biopsy market with significant technological innovations and high adoption rates. Major companies are developing advanced platforms for early cancer detection and monitoring. Regulatory agencies like the FDA have approved several liquid biopsy tests, boosting clinical integration. The focus is on personalized medicine, with extensive research funding supporting new biomarker discoveries. The healthcare infrastructure and reimbursement policies favor widespread adoption, making the US a key driver of market growth.
- China: China is rapidly expanding its liquid biopsy market, driven by a large patient population and government initiatives to enhance cancer diagnostics. Local companies are developing cost-effective solutions tailored to regional needs. Increasing investments in biotech research and collaborations with international firms accelerate innovation. Regulatory frameworks are evolving to facilitate faster approval processes. The market is also benefiting from rising awareness and demand for minimally invasive diagnostic options, positioning China as a significant emerging player.
- Germany: Germany's market growth is supported by a strong healthcare system and a focus on precision medicine. Leading biotech firms and research institutions are advancing liquid biopsy technologies for cancer management. Regulatory approval processes are streamlined, encouraging innovation. The country emphasizes clinical validation and integration into standard care protocols. Investments in research and development, along with collaborations across Europe, bolster Germany's position as a key market for advanced liquid biopsy solutions.
- India: India's liquid biopsy market is in its nascent stages but shows promising growth potential. The increasing burden of cancer and rising awareness are driving demand for early detection tools. Local startups and international companies are introducing affordable, scalable solutions suitable for the Indian population. Government initiatives to improve healthcare infrastructure and promote biotech innovation support market expansion. Challenges include regulatory hurdles and limited reimbursement, but ongoing efforts aim to address these barriers and foster market development.
- Japan: Japan's market is characterized by high technological adoption and a focus on innovative healthcare solutions. Leading companies are developing highly sensitive liquid biopsy tests for various cancers. The government's support for precision medicine and aging population drives demand for early diagnostic tools. Regulatory pathways are well-established, facilitating product approvals. Collaborations between academia and industry enhance research and development. Japan's emphasis on quality and innovation positions it as a mature and competitive market in the liquid biopsy sector.
Features of the Global Liquid Biopsy Market
- Market Size Estimates: liquid biopsy market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: liquid biopsy market size by various segments, such as by product, circulating biomarker, application, end use, and region in terms of value ($M).
- Regional Analysis: liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, circulating biomarker, application, end use, and regions for the liquid biopsy market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the liquid biopsy market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and others), application (oncology and non-cancer), end use (reference laboratories, hospitals & physician laboratories, academic & research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?